buy call option jak develop ibd
show stori
wednesday market open sell pt
develop treatment crohn diseas ulcer
coliti although jak inhibitor similar filgotinib drug
unselect across jak isoform also design limit
absorpt gi tract overal dataset limit
across effort ibd unselect jak and/or restrict
absorpt approach fare well furthermor structur
deal essenti call option look phase dataset
commit develop think smart move
reiter buy rate pt
unselect pan-jak inhibitor written
numer time hit creat hematolog toxic
problem target auto-immun disord
deleteri dvt/ pe event associ unselect jak
inhibitor baricitinib potenc across jak
isoform pki valu
look circumv toxic issu restrict
absorpt outsid gi tract in-human data limit
seem drug prefer absorpt within colon
restrict absorpt may help therapeut window
ulcer coliti inflamm occur crohn limit
colon furthermor mongersen recent fail
indic use restrict absorpt premis well
clinic data look publish therav
report top-lin result august find
formal present public phase studi
point could agre seem activ base upon
mayo score studi lack disclosur
provid assess clinic effect compani plan
start phase program
valuat valu glpg ev/ sale
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
wednesday market open sell pt
therav rate announc collabor agreement
develop treatment crohn diseas ulcer
coliti although jak inhibitor similar filgotinib drug
unselect across jak isoform also design limit
absorpt gi tract overal dataset limit
across effort ibd unselect jak and/or restrict absorpt
approach fare well furthermor structur deal
essenti call option look phase dataset
commit develop think smart move
reiter buy rate pt
figur develop plan
galapago inc incom statement good margin develop administr market market profit margin valu re-measur share sub financi financi tax share share ep growth yoynon-gaap adjustmentsgaap epsshar
btig cover compani mention report
appendix analyst certif import disclosur
